Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The increased expression level of CASC4 is associated with HER-2/neu proto-oncogene overexpression. Additionally we are shipping Cancer Susceptibility Candidate 4 Antibodies (24) and Cancer Susceptibility Candidate 4 Proteins (5) and many more products for this protein.
In spite of missing correlation between survival and her-2/ neu (show ERBB2 ELISA Kits) overexpression in our study, the predictive value of the her-2/ neu (show ERBB2 ELISA Kits) protooncogene in adjuvant therapy in OSCC needs further investigation.
Of 62 analyzed specimens, 43 tumors were HER2/neu (show ERBB2 ELISA Kits) negative compared to 19 HER2/neu (show ERBB2 ELISA Kits) positive tumors. Kaplan-Meier analysis indicated no difference in survival according to HER2/neu (show ERBB2 ELISA Kits) expression (p = 0.31, log-rank test = 1.10
The increased expression level of this gene is associated with HER-2/neu proto-oncogene overexpression. Amplification and resulting overexpression of this proto-oncogene are found in approximately 30% of human breast and 20% of human ovarian cancers. Alternatively spliced variants encoding different isoforms have been identified for this gene.
cancer susceptibility candidate gene 4 protein
, gene associated with HER-2/neu overexpression
, protein CASC4
, cancer susceptibility candidate gene 4 protein homolog